Predictors of Recurrent Ischemic Stroke in Patients Wit Undetermined Source and Effects of Rivaroxaban Versu Status: The NAVIGATE ESUS Trial

Journal of Stroke and Cerebrovascular Diseases

28, 2273-2279

DOI: 10.1016/j.jstrokecerebrovasdis.2019.05.014

Citation Report

#	Article	IF	Citations
1	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. Stroke, 2019, 50, 3184-3190.	9.1	92
2	Clinical Classification and the Subclinical Atrial Fibrillation Challenge: A Position Paper of the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 495-507.	2.7	8
3	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurology, 2020, 77, 1233-1240.	22.0	60
4	Stroke Prevention in Atrial Fibrillation. Circulation, 2020, 142, 2371-2388.	24.6	95
5	Left Atrial Volume Index Predicts New-Onset Atrial Fibrillation and Stroke Recurrence in Patients With Embolic Stroke of Undetermined Source. Cerebrovascular Diseases, 2020, 49, 285-291.	2.1	44
6	Characteristics and Outcomes of Embolic Stroke of Undetermined Source According to Stroke Severity. International Journal of Stroke, 2020, 15, 866-871.	7.4	8
7	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 2386-2394.	9.1	25
8	Rivaroxaban Versus Aspirin for Secondary Prevention of Ischaemic Stroke in Patients With Cancer: A Subgroup Analysis of the NAVIGATE ESUS Randomized Trial. European Journal of Neurology, 2020, 27, 841-848.	4.4	56
9	Embolic Stroke of Undetermined Source and Sleep Disorders. Stroke, 2020, 51, 1294-1296.	9.1	11
10	Vergangenheit und Zukunft des ESUS-Konzepts. Der Nervenarzt, 2020, 91, 511-517.	1.3	3
11	Diagnosis and Treatment for Embolic Stroke of Undetermined Source: Consensus Statement From the Taiwan Stroke Society and Taiwan Society of Cardiology. Journal of the Formosan Medical Association, 2021, 120, 93-106.	2.2	9
12	Cumulative Risk of Stroke Recurrence Over the Last 10 Years: A Systematic Review and Meta-Analysis. Neurological Sciences, 2021, 42, 61-71.	2.4	121
13	The Utility of the Markers of Coagulation and Hemostatic Activation Profile in the Management of Embolic Strokes of Undetermined Source. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105592.	2.2	11
14	Characteristics and Prognosis of Patients With Embolic Stroke of Undetermined Source in China. International Journal of Stroke, 2022, 17, 526-535.	7.4	3
15	D-Dimer Level as a Predictor of Recurrent Stroke in Patients With Embolic Stroke of Undetermined Source. Stroke, 2021, 52, 2292-2301.	9.1	28
16	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke, 2022, 53, 45-52.	9.1	16
17	Embolic Stroke of Undetermined SourceESUS. Nosotchu, 2022, 44, 119-126.	0.2	1
18	A Critical Assessment of the Current Pharmacotherapy for the Treatment of Embolic Strokes of Undetermined Source. Expert Opinion on Pharmacotherapy, 2022, 23, 905-915.	3.5	4

#	Article	IF	Citations
19	Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. Journal of the American Heart Association, 2022, 11, e023545.	5.8	14
20	A Score to Predict the Stroke Recurrence of Patients With Embolic Stroke of Undetermined Source. Journal of Neurology, 2022, 269, 6428-6435.	5.4	2
21	Controversies in Stroke: Should Patients With Embolic Stroke of Undetermined Source Undergo Intensive Heart Rhythm Monitoring With an Implantable Loop Recorder?. Stroke, 2022, 53, 3243-3247.	9.1	16
22	A Systematic Review and Meta-Analysis of Carotid Artery Stenting for the Treatment of Cervical Carotid Artery Dissection. European Journal of Vascular and Endovascular Surgery, 2022, 64, 299-308.	3.2	23
23	Embolic Stroke of Undetermined Source: Current Perspectives on Diagnosis, Investigations, and Management. Canadian Journal of Cardiology, 2023, 39, 172-186.	3.8	5
24	Cardiovascular Outcomes and Mortality After Incident Ischaemic Stroke in Patients With a Recent Cancer History. European Journal of Internal Medicine, 2023, 109, 50-57.	4.2	5
25	Risk of Recurrent Stroke and Mortality After Cryptogenic Stroke in Diabetic Patients. Heart and Vessels, 2023, 38, 817-824.	1.8	0
26	ECG Smart Monitoring Versus Implantable Loop Recorders for Atrial Fibrillation Detection After Cryptogenic Stroke—An Overview for Decision Making. Journal of Cardiovascular Development and Disease, 2023, 10, 306.	2.9	9
27	Left Atrial Strain Predicts Stroke Recurrence and Death in Patients With Cryptogenic Stroke. American Journal of Cardiology, 2024, 210, 51-57.	2.4	13
28	Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation. Neurology, 2025, 105, e213876.	5.0	10
29	Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial. Stroke, 2026, 57, 570-576.	9.1	0
30	Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis. Stroke, 2026, 57, 650-661.	9.1	1